Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Gribben

Showing results (61-70 of 104) with videos related to

Pageof 11
Sort By:
Leukemia|August 30, 2019
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trialChristiane Pott, Laurie H Sehn, David Belada, et al.
The Journal of Biological Chemistry|March 13, 2020
Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK functionEssam A Ghazaly, Farideh Miraki-Moud, Paul Smith, et al.
Cell Stem Cell|October 8, 2013
HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stressKevin Rouault-Pierre, Lourdes Lopez-Onieva, Katie Foster, et al.
Scientific Reports|March 7, 2019
Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cellsMichelle R Goulart, Sabina I Hlavaty, Yu-Mei Chang, et al.
Cell Reports|May 3, 2019
Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 DegradationDijue Sun, Urszula Stopka-Farooqui, Sayka Barry, et al.
Signal Transduction and Targeted Therapy|February 27, 2023
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypesPedro Casado, Ana Rio-Machin, Juho J Miettinen, et al.
Haematologica|May 2, 2016
Role of the tumor microenvironment in mature B-cell lymphoid malignanciesNathan H Fowler, Chan Yoon Cheah, Randy D Gascoyne, et al.
Expert Review of Anticancer Therapy|February 1, 2023
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphomaM Lia Palomba, Paola Ghione, Anik R Patel, et al.
Frontiers in Oncology|March 27, 2020
Gene Expression Profiling of B Cell Lymphoma in Dogs Reveals Dichotomous Metabolic Signatures Distinguished by Oxidative PhosphorylationYing Wu, Yu-Mei Chang, Gerry Polton, et al.
Oncogene|October 27, 2023
SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AMLAntonella Di Mambro, Yoana Arroyo-Berdugo, Tiziana Fioretti, et al.
Pageof 11

Showing results (61-70 of 104) with videos related to

Sort By:
Pageof 11
Leukemia|August 30, 2019
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trialChristiane Pott, Laurie H Sehn, David Belada, et al.
The Journal of Biological Chemistry|March 13, 2020
Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK functionEssam A Ghazaly, Farideh Miraki-Moud, Paul Smith, et al.
Cell Stem Cell|October 8, 2013
HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stressKevin Rouault-Pierre, Lourdes Lopez-Onieva, Katie Foster, et al.
Scientific Reports|March 7, 2019
Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cellsMichelle R Goulart, Sabina I Hlavaty, Yu-Mei Chang, et al.
Cell Reports|May 3, 2019
Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 DegradationDijue Sun, Urszula Stopka-Farooqui, Sayka Barry, et al.
Signal Transduction and Targeted Therapy|February 27, 2023
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypesPedro Casado, Ana Rio-Machin, Juho J Miettinen, et al.
Haematologica|May 2, 2016
Role of the tumor microenvironment in mature B-cell lymphoid malignanciesNathan H Fowler, Chan Yoon Cheah, Randy D Gascoyne, et al.
Expert Review of Anticancer Therapy|February 1, 2023
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphomaM Lia Palomba, Paola Ghione, Anik R Patel, et al.
Frontiers in Oncology|March 27, 2020
Gene Expression Profiling of B Cell Lymphoma in Dogs Reveals Dichotomous Metabolic Signatures Distinguished by Oxidative PhosphorylationYing Wu, Yu-Mei Chang, Gerry Polton, et al.
Oncogene|October 27, 2023
SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AMLAntonella Di Mambro, Yoana Arroyo-Berdugo, Tiziana Fioretti, et al.
Pageof 11